Can a daily nudge cut deadly bloodstream infections?
NCT ID NCT07746674
First seen Aug 05, 2026 · Last updated Aug 06, 2026 · Updated 1 time
Summary
This study tests whether a daily electronic alert can help reduce unnecessary use of central venous catheters (CVCs) in hospitalized adults. The alert flags patients with an active CVC but no documented reason for it, prompting the care team to reassess and document whether the line is still needed. The goal is to reduce the number of days patients have a central line without a clear indication, thereby lowering the risk of central line-associated bloodstream infections (CLABSI). The trial compares this alert intervention to usual care in a small group of adult patients.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- A daily electronic health record alert prompting clinicians to document the necessity of a central line
- What this could lead to
- If effective, this simple alert could reduce unnecessary central line days and lower the risk of serious bloodstream infections in hospitals.
- What could go wrong
- The trial is small and early, and the alert's impact may be limited by clinician adherence or existing practices. It may not generalize to all hospital settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 30 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult inpatients with an active central venous catheter for at least 24 hours who meet alert eligibility criteria during the study period
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Not hospice patient class * Active central line for at least 24 hours Exclusion Criteria: * No active central line * Central line present for less than 24 hours
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Central line-associated bloodstream infection (clabsi) are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
NYU Langone Health
New York, New York, 10016, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.